GlaxoSmithKline
GSK
#215
Rank
$81.27 B
Marketcap
$39.86
Share price
2.47%
Change (1 day)
15.50%
Change (1 year)

P/E ratio for GlaxoSmithKline (GSK)

P/E ratio as of July 2024 (TTM): 11.1

According to GlaxoSmithKline's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 11.112. At the end of 2022 the company had a P/E ratio of 4.14.

P/E ratio history for GlaxoSmithKline from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
20224.14-71.88%
202114.745.85%
202010.1-35.71%
201915.7-0.75%
201815.8-55.39%
201735.5-44.04%
201663.4919.49%
20156.22-66.06%
201418.354.42%
201311.90.16%
201211.97.42%
201111.0-64.77%
201031.3219.92%
20099.796.19%
20089.22-12.84%
200710.6-11.42%
200611.9-12.62%
200513.7-10.16%
200415.21.29%
200315.0-17.25%
200218.1-42.66%
200131.7

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
39.6 256.30%๐Ÿ‡ฌ๐Ÿ‡ง UK
15.9 42.73%๐Ÿ‡บ๐Ÿ‡ธ USA
68.9 519.69%๐Ÿ‡บ๐Ÿ‡ธ USA
29.6 165.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
15.7 41.63%๐Ÿ‡ซ๐Ÿ‡ท France
-8.33-174.92%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
12.5 12.44%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.